FDA Fast Tracks SELLAS Life Sciences' CDK9 Inhibitor for Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc’s CDK9 inhibitor SLS009 is being evaluated in an ongoing Phase I/II study in combination with Venclexta and Vidaza for patients with relapsed or refractory acute myeloid leukemia.

Source link
#FDA #Fast #Tracks #SELLAS #Life #Sciences039 #CDK9 #Inhibitor #Acute #Myeloid #Leukemia